KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Moderna (MRNA) EBIAT (2017 - 2025)

Moderna (MRNA) has disclosed EBIAT for 9 consecutive years, with -$826.0 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 26.25% to -$826.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 billion through Dec 2025, up 20.75% year-over-year, with the annual reading at -$2.8 billion for FY2025, 20.75% up from the prior year.
  • EBIAT for Q4 2025 was -$826.0 million at Moderna, down from -$200.0 million in the prior quarter.
  • The five-year high for EBIAT was $4.9 billion in Q4 2021, with the low at -$3.6 billion in Q3 2023.
  • Average EBIAT over 5 years is $473.4 million, with a median of $46.0 million recorded in 2023.
  • The sharpest move saw EBIAT soared 2476.07% in 2021, then crashed 1638.46% in 2025.
  • Over 5 years, EBIAT stood at $4.9 billion in 2021, then tumbled by 69.91% to $1.5 billion in 2022, then plummeted by 85.19% to $217.0 million in 2023, then plummeted by 616.13% to -$1.1 billion in 2024, then rose by 26.25% to -$826.0 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$826.0 million, -$200.0 million, and -$825.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.